Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

John David Chetwood Yvonne Tran Sreedhar Subramanian Philip J SmithMarisa IborraAnthony BuissonSudarshan ParamsothyRupert W L Leongnull null

Published in: Journal of Crohn's & colitis (2024)

Changing patients established on IV infliximab to an SC formulation is associated with a high ongoing clinical remission and low adverse event rate. Furthermore, there are no signals for adverse outcomes among different IBD disease subtypes, nor in those on escalated IV infliximab dosing schedules up to 10mg/kg 6-weekly. This data should provide patients and clinicians alike with confidence in SC infliximab use in IBD.

Keyphrases

deep learning
end stage renal disease
ulcerative colitis
machine learning
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
emergency department
rheumatoid arthritis
high dose
big data
disease activity